Literature DB >> 11150917

Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia.

H B Jiang1, H Yoneyama, A Furukawa, T Hamamoto, J Takahara, Y Ichikawa.   

Abstract

Nitric oxide synthase (NOS) catalyzes nitric oxide (NO) formation from L-arginine in the presence of molecular oxygen and NADPH. NO is involved in the regulation of microvasculature. Isosorbide dinitrate (ISDN) and glyceryl trinitrate (GTN) have been widely used as vasodilators to treat acute myocardial ischemia, their biological effects being due to the release of NO. In this investigation, the effects of ISDN and GTN on NOS activity in the presence or absence of oxyhemoglobin under hypoxia and normoxia were studied. The apparent K(m) values for molecular oxygen were 21.6 +/- 1.5 and 9.4 +/- 1.3 micromol/l for nNOS and eNOS, respectively. ISDN liberated NO in a concentration- and pH-dependent manner, but no differences between hypoxia and normoxia were observed. The NO release from ISDN was also measured directly by an electron spin resonance spectral method with N-(dithiocarboxy)sarcosine-Fe complex as a NO-trapping agent. ISDN increased nNOS and eNOS activities in the presence of 30 micromol/l oxyhemoglobin under hypoxia, while it did not affect nNOS and eNOS activities under normoxia. In the absence of oxyhemoglobin, ISDN inhibited nNOS and eNOS activities under both hypoxic and normoxic experimental conditions. The rate of oxygen release from oxyhemoglobin under hypoxia was increased 3 times in the presence of 1 mmol/l ISDN. In contrast to ISDN, GTN could not release NO spontaneously, and it also did not affect nNOS and eNOS activities in the absence or presence of 30 micromol/l oxyhemoglobin under both hypoxic and normoxic conditions. These results indicated that the NO release from ISDN is different from that of GTN, and the increase of NOS activity by ISDN in the presence of oxyhemoglobin under hypoxia is ascribed to the increase in molecular oxygen concentration. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150917     DOI: 10.1159/000056066

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  6 in total

Review 1.  Spreading Depolarizations and Subarachnoid Hemorrhage.

Authors:  Kazutaka Sugimoto; David Y Chung
Journal:  Neurotherapeutics       Date:  2020-04       Impact factor: 7.620

2.  Factors Associated with Nitric Oxide-mediated β2 Integrin Inhibition of Neutrophils.

Authors:  Veena M Bhopale; Ming Yang; Kevin Yu; Stephen R Thom
Journal:  J Biol Chem       Date:  2015-06-01       Impact factor: 5.157

3.  A role of the sodium pump in spreading ischemia in rats.

Authors:  Sebastian Major; Gabor C Petzold; Clemens Reiffurth; Olaf Windmüller; Marco Foddis; Ute Lindauer; Eun-Jeung Kang; Jens P Dreier
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

4.  Questioning Glutamate Excitotoxicity in Acute Brain Damage: The Importance of Spreading Depolarization.

Authors:  R David Andrew; Eszter Farkas; Jed A Hartings; K C Brennan; Oscar Herreras; Michael Müller; Sergei A Kirov; Cenk Ayata; Nikita Ollen-Bittle; Clemens Reiffurth; Omer Revah; R Meldrum Robertson; Ken D Dawson-Scully; Ghanim Ullah; Jens P Dreier
Journal:  Neurocrit Care       Date:  2022-02-22       Impact factor: 3.532

Review 5.  Migraine Aura, Transient Ischemic Attacks, Stroke, and Dying of the Brain Share the Same Key Pathophysiological Process in Neurons Driven by Gibbs-Donnan Forces, Namely Spreading Depolarization.

Authors:  Coline L Lemale; Janos Lückl; Viktor Horst; Clemens Reiffurth; Sebastian Major; Nils Hecht; Johannes Woitzik; Jens P Dreier
Journal:  Front Cell Neurosci       Date:  2022-02-10       Impact factor: 6.147

6.  Neuroprotective effect of nitric oxide donor isosorbide-dinitrate against oxidative stress induced by ethidium bromide in rat brain.

Authors:  Omar M E Abdel-Salam; Yasser Ashry Khadrawy; Nadia A Mohammed
Journal:  EXCLI J       Date:  2012-03-29       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.